In addition, our data show that AMD3100 can abrogate the survival effect of CXCL12–CXCR4 signalling and can serve as a therapeutic modality either alone or in combination with gemcitabine to effectively inhibit the growth of pancreatic cancer cells. Here, CXCL12 is linked to familial pancreatic carcinoma.